Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab.
In the search for new pharmacologic therapies for central giant cell granuloma (CGCG), proteins that are essential to osteoclastogenesis are intriguing potential targets. In the present case report, we describe a 25-year-old patient with an aggressive CGCG of the maxilla, who was successfully treated with the antiresorptive agent denosumab, after other pharmacologic treatment had failed to achieve regression or stabilization of the tumor. Denosumab could be a promising alternative to potentially mutilating surgery for CGCG. However, more research is needed before definite conclusions can be drawn about the potential role of this agent in the treatment of CGCG.
Oral and Maxillofacial Surgeon, Department of Oral and Maxillofacial Surgery, Academic Medical Center, Academic Center Dentistry Amsterdam, University of Amsterdam, Amsterdam, The Netherlands; Fellow Head and Neck Surgery, Department of Head and Neck Surgery, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: w.h.schreuder@amc.uva.nl.
Willem H
WH
Schreuder
Attending Physician, Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Annet W
AW
Coumou
Professor and Chair of Oral and Maxillofacial Surgery, Department of Cranio-Maxillo-Facial Surgery, University Hospital Maastricht, Maastricht University, Maastricht, The Netherlands.
Peter A H W
PA
Kessler
Professor and Chair of Oral and Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, Academic Medical Center, Academic Center Dentistry Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
Jan
J
de Lange
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000069448:Denosumab; D005260:Female; D006101:Granuloma, Giant Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009062:Mouth Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D014057:Tomography, X-Ray Computed
D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab